The study found that people with the debilitating condition had “significantly lower” levels of caffeine in their blood than people without the disease – even if they consumed the same amount of caffeine.
Study author Doctor Shinji Saiki, of Juntendo University School of Medicine in Japan, said: “Previous studies have shown a link between caffeine and a lower risk of developing Parkinson’s disease, but we haven’t known much about how caffeine metabolises within the people with the disease.”
People in the study with more severe stages of the disease did not have lower levels of caffeine in the blood, suggesting that the decrease occurs from the earliest stages of the disease, according to Doctor David Munoz, of the University of Toronto in Canada, who wrote an editorial accompanying the study.
He said: “If these results can be confirmed, they would point to an easy test for early diagnosis of Parkinson’s, possibly even before symptoms are appearing.
This is important because Parkinson’s disease is difficult to diagnose, especially at the early stages.”
The study involved 108 people who had Parkinson’s for an average of about six years and 31 people of the same age who didn’t have the disease.
Their blood was tested for caffeine and for 11 byproducts the body makes as it metabolises caffeine. They were also tested for mutations in genes that can affect caffeine metabolism.
The two groups consumed about the same amount of caffeine, with an average equival
But the people with Parkinson’s disease had significantly lower blood levels of caffeine and nine of the 11 byproducts of caffeine in the blood, according to the findings published online by the journal Neurology.
The caffeine level was an average of 79 picomoles per 10 microlitres for people without Parkinson’s disease, compared to 24 picomoles per 10 microlitres for people with the disease.
For one of the byproducts, the level was below the amount that could be detected in more than half of the people with Parkinson’s disease.
In the statistical analysis, the researchers found that the test could be used to reliably identify the people with Parkinson’s disease, with a score of 0.98 where a score of one means that all cases are identified correctly.
In the genetic analysis, there were no differences in the caffeine-related genes between the two groups.
Dr Saiki said limitations of the study include that people with severe Parkinson’s were not included, which could affect the ability to detect an association between disease severity and caffeine levels.
Dr Munoz also noted that all of the people with Parkinson’s were taking Parkinson’s medication and it’s possible that these drugs could affect the metabolism of caffeine.